Brandon Miranda

ENGL 21003

Professor Zayas

October 2, 2025

Tatsuro Misu. (2025). Myelin oligodendrocyte glycoprotein antibody-associated disease: pathophysiology, clinical patterns, and therapeutic challenges of intractable and severe forms. International Journal of Molecular Sciences, 26 (17), 8538-8538. https://doi.org/10.3390/ijms26178538

This article “Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Pathophysiology, Clinical Patterns, and Therapeutic Challenges of Intractable and Severe Forms” addresses the multiclinical trials and tests into the cellular level of MOG and  MOG-IgG antibodies. These antibodies compromise T cell structure, activate complement-dependent cytotoxicity that create the various types of lesions resulting differently in various disabling factors for a patient. Tatsuro acknowledges the unpredictability in the IgG1 autoantibodies and the severity of activation that occurs in MOGAD patients as the varying degrees can either distinguish a simple recovery versus a grueling relapse with minimal immunotherapy assistance. Tatsuro aimed to start tying the research available together to understand and to advocate for the unification of research.

Connection:

For the bulk of my research, I will have to divulge at the cellular level, the antecedents and consequences of these MOG-IgG antibodies developing, especially with regard to the radical behavior of the disease itself within patients. This article suffices my requirement to establish the baseline understanding of how MOGAD is distinguished from its superfamily of diseases such as: MS, NSMOD, or AQP4. Particularly how strange and unique this disease presents itself as compared to the well endowed view into the other related illnesses MOGAD shares pathologies with.

Quotes:

• “MOGAD is pathologically distinct from MS and aquaporin-4 (AQP4)-IgG+ NMOSD and exhibits characteristic features that reflect its unique immunopathogenesis [13]. Perive-nous demyelination and the dominance of CD4+ T-cell infiltration [7,14], along with granulocytes such as neutrophils and eosinophils, often reminiscent of monophasic ADEM, are considered hallmarks of MOGAD in the acute stage [15].” (Tatsuro 2025, p. 2)
• “The isotypes of autoantibodies against MOG and AQP4 are mainly IgG1 that can mediate complement-dependent cytotoxicity (CDC) [19] in addition to antibody-mediated  cytotoxicity (ADCC) [20].” (Tatsuro 2025, p. 3)
• “Although most cases of MOGAD respond favorably to corticosteroids and immunother- apy, a subset of patients experience severe or refractory disease, defined by criteria such as poor functional recovery; early relapse during sequential acute immunotherapy, including IVIG and plasma exchange (PLEX); and resistance to corticosteroids and immunosuppressants such as azathioprine, tacrolimus, mycophenolate mofetil, or other maintenance therapies [46,50,51].” (Tatsuro 2025, p. 7)

 Zhang, Y.-N et al. (2025). Myelin oligodendrocyte glycoprotein antibody-associated disease presenting as aseptic meningitis and multiple cranial neuritis: a case report. BMC Neurology, 25 (1). https://doi.org/10.1186/s12883-025-04287-1

This case study “Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Presenting as Aseptic Meningitis and Multiple Cranial Neuritis: A Case Report” done by Zhang et al. was a conformity to a more rare and peculiar case of MOGAD development, in which now countered the idea that a patient of MOGAD could not have manifestations of aseptic meningitis and cranial neuritis simultaneously. This was found by a patient treated by Zhang et al. at the General Hospital of Northern Theater in Shenyang, China. The fifty-nine year old male, was discovered to contain both symptoms when immunotherapy was administered, and both a positive and negative reaction occurred within the patient which unfortunately led to their passing. This had Zhang et al. call for a refinement of the possibility the MOG antibody may induce and to approach cautiously since much is still unknown.

Connection:

For the basis of my research paper, I want to establish much of what is still unknown in terms of the research conducted into MOGAD and the realm of possibilities this disease can take as research adapts to understand it. I believe this case study is a pain stakingly relevant example of the matter. While science on MOGAD and general idea is consistent and is further being incorporated into newer research, there remains an abundance of information not yet discovered, submerged into the depths of unexplored research sitting dormant, waiting for the opportunity of new hypotheses to uncover the true limits of MOGAD disease. I will divulge this information as one of a pair as two prime examples of extraordinary findings and possibility that scientists require collaborative attention.

Quotes:

• “A 59-year-old male was 160 cm in height and 45 kg in weight. He was thin yet healthy before the onset of the current illness, with no unhealthy lifestyle habits except for smoking. The patients denied any history of preceding infections or vaccinations.” (Zhang et al. 2025, p. 2)
• “The patient was diagnosed with MOGAD and initiated treatment with intravenous methylprednisolone (1,000 mg/day for 3 days, 500 mg/day for 3 days, 250 mg/day for 3 days, and 125 mg/day for 3 days), followed by a tapering course of oral prednisolone…After 12 days of methylprednisolone, the patient’s headache symptoms were significantly relieved, while cranial neuritis worsened with left blepharoptosis, immobility of left ocular bulbar, and restricted outward movement of the right eyeball, tongue deviation to the left upon protrusion, decreased bilateral pharyngeal reflex, and dysphagia, which indicated that the left oculomotor nerve, bilateral abducens nerves, left hypoglossal nerve, and bilateral glossopharyngeal nerves were paralyzed.” (Zhang et al. 2025, p. 2)
• “In our case, methylprednisolone treatment led to divergent outcomes for the presenting symptoms. Relieved headache and lepto-meningeal enhancement in MRI suggested that aseptic meningitis was improved. Conversely, the exacerbation of extraocular muscle paralysis and new onset of lingual and glossopharyngeal muscles paralysis suggested that cranial neuritis was aggravated. The underlying mechanisms responsible for this contrasting response between meningitis and neuritis are not well understood.” (Zhang et al. 2025, p.4)